CARDIOVASCULAR SYSTEMS INC (CSII)
US1416191062 - Common Stock
Taking everything into account, CSII scores 3 out of 10 in our fundamental rating. CSII was compared to 188 industry peers in the Health Care Equipment & Supplies industry. CSII scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CSII is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CSII had negative earnings in the past year.
In the past year CSII has reported a negative cash flow from operations.
CSII had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CSII reported negative operating cash flow in multiple years.
1.2 Ratios
CSII has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CSII has a Gross Margin of 72.39%. This is amongst the best in the industry. CSII outperforms 82.46% of its industry peers.
CSII's Gross Margin has declined in the last couple of years.
CSII does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-1.96%
2. Health
2.1 Basic Checks
CSII does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CSII has been increased compared to 1 year ago.
The number of shares outstanding for CSII has been increased compared to 5 years ago.
The debt/assets ratio for CSII is higher compared to a year ago.
2.2 Solvency
CSII has an Altman-Z score of 6.06. This indicates that CSII is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CSII (6.06) is better than 80.57% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that CSII is not too dependend on debt financing.
CSII has a Debt to Equity ratio (0.08) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.06 |
ROIC/WACCN/A
WACC9.65%
2.3 Liquidity
A Current Ratio of 6.04 indicates that CSII has no problem at all paying its short term obligations.
The Current ratio of CSII (6.04) is better than 72.99% of its industry peers.
CSII has a Quick Ratio of 4.92. This indicates that CSII is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.92, CSII is doing good in the industry, outperforming 72.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.04 | ||
| Quick Ratio | 4.92 |
3. Growth
3.1 Past
The earnings per share for CSII have decreased strongly by -46.97% in the last year.
CSII shows a decrease in Revenue. In the last year, the revenue decreased by -4.73%.
Measured over the past years, CSII shows a small growth in Revenue. The Revenue has been growing by 2.89% on average per year.
EPS 1Y (TTM)-46.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)-4.73%
Revenue growth 3Y-1.61%
Revenue growth 5Y2.89%
Sales Q2Q%3.92%
3.2 Future
CSII is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.08% yearly.
The Revenue is expected to grow by 10.69% on average over the next years. This is quite good.
EPS Next Y28.21%
EPS Next 2Y21.47%
EPS Next 3Y19.08%
EPS Next 5YN/A
Revenue Next Year8.64%
Revenue Next 2Y9.57%
Revenue Next 3Y10.69%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CSII. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CSII. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CSII's earnings are expected to grow with 19.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.47%
EPS Next 3Y19.08%
5. Dividend
5.1 Amount
CSII does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARDIOVASCULAR SYSTEMS INC
NASDAQ:CSII (4/27/2023, 8:22:19 PM)
After market: 20 0 (0%)20
+0.03 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap839.18M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.39% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.04 | ||
| Quick Ratio | 4.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-46.97%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y28.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.73%
Revenue growth 3Y-1.61%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y